☆ 4.7 Article

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

BLOOD (2022)

Related references

Note: Only part of the references are listed.

Article Pathology

Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas

Paul A. Christensen et al.

Summary: The Omicron variant of SARS-CoV-2 has rapidly spread worldwide and is now responsible for the majority of COVID-19 cases. A study found that patients infected with Omicron were younger, had higher vaccine breakthrough rates, and were less likely to be hospitalized compared to patients with other variants. They also required less respiratory support and had shorter hospital stays, indicating reduced disease severity.

AMERICAN JOURNAL OF PATHOLOGY (2022)

Add to Collection

Article Hematology

COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA

Livio Pagano et al.

BLOOD (2022)

Add to Collection

Article Hematology

Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting

Moshe Mittelman et al.

Summary: Limited evidence suggests that COVID-19 vaccines may be less effective in patients with impaired immunity. A study on patients with hematological neoplasms showed that vaccinated patients had a higher risk of COVID-19 infection, hospitalization, and death compared to vaccinated controls. Patients receiving treatment had an even higher risk. Ways to enhance COVID-19 immunity in this patient population should be explored.

BLOOD (2022)

Add to Collection

Review Hematology

COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research

Lindsey Wang et al.

Summary: This study shows that among the fully vaccinated population, patients with hematologic malignancies (HM) had a significantly higher risk for breakthrough infections compared to patients without cancer. Breakthrough infections in patients with HM were associated with higher rates of hospitalization and mortality.

BLOOD REVIEWS (2022)

Add to Collection

Article Hematology

T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies

Vincenzo Marasco et al.

Summary: The study evaluated the serological and T-cell responses of lymphoid malignancy patients after mRNA vaccination, finding that some patients, especially those receiving anti-CD20 antibody treatment, may not effectively develop protective antibodies. T-cell responses were detected in most patients, even in seronegative individuals, but a small percentage of cases had no cellular or humoral responses. This raises concerns about the vaccine efficacy for LM patients, highlighting the need for continued protective measures.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Hematology

Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres

Ondrej Susol et al.

Summary: The mRNA COMIRNATY vaccine has been administered to 392 patients with a two-dose regimen, resulting in an overall antibody response of 70%. The initial results of administering a third dose to 80 patients who did not achieve seroconversion or had a weak response show promise, especially for patients on anti-CD38 therapy.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Oncology

Original Research Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events - a retrospective cohort study

Maximilian J. Mair et al.

Summary: This study demonstrates improved antibody levels in patients with cancer after the third vaccination dose with an acceptable side-effect profile. However, lower antibody levels compared to controls highlight the need for further follow-up studies and dedicated trials.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

News Item Medicine, General & Internal

Nature does things well

[Anonymous]

EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2022)

Add to Collection

Article Immunology

Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States

Mark W. Tenforde et al.

Summary: From March to May 2021, full vaccination using authorized mRNA products was associated with 87.1% protection against COVID-19 hospitalization among US adults, with lower effectiveness in adults with immunosuppression compared to those without. Vaccination was beneficial for patients with immunosuppression, but the effectiveness was lower in this population.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Letter Hematology

Infections with the SARS-CoV-2 Omicron variant show a similar outcome as infections with the previous variants in patients with hematologic malignancies

Ryutaro Taenaka et al.

ANNALS OF HEMATOLOGY (2022)

Add to Collection

Article Oncology

COVID-19 vaccination and breakthrough infections in patients with cancer

A. L. Schmidt et al.

Summary: This study analyzes the clinical features of cancer patients who develop symptomatic COVID-19 after vaccination. It finds that these patients often have comorbidities and can experience severe and even lethal infections. Hematologic malignancy patients are over-represented among the vaccinated cancer patients who develop symptomatic COVID-19. Therefore, while vaccination remains crucial in protecting vulnerable populations, including cancer patients, those who develop breakthrough infections despite full vaccination still face the risk of severe outcomes.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Hematology

Patients with CLL have a lower risk of death from COVID-19 in the Omicron era

Carsten U. Niemann et al.

Summary: "Previous studies have shown high mortality rates in patients with chronic lymphocytic leukemia (CLL) and coronavirus disease 2019 (COVID-19). Although the Omicron variant is considered to have a milder disease course in the general population, the outcome for immunocompromised patients has not been reported previously. A study found that hospitalization and intensive care unit admission rates significantly declined in CLL patients during the period when the Omicron sublineage BA.2 variant dominated, but the 30-day mortality remained high. However, for a larger population-based cohort of CLL patients, including those in hospitals, the 30-day mortality was 2%. Therefore, close monitoring and preemptive antiviral therapy should be considered for CLL patients with close hospital contacts, especially those >70 years old with comorbidities, upon a positive SARS-CoV-2 test."

BLOOD (2022)

Add to Collection

Letter Oncology

Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas

Francesco Marchesi et al.

LEUKEMIA (2022)

Add to Collection

Article Medicine, General & Internal

Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study

Tommy Nyberg et al.

Summary: The Omicron variant shows lower severity compared to Delta, especially in terms of hospital admission and death, with significant variations by age. Unvaccinated cases experience a larger reduction in intrinsic severity, while vaccinated cases experience reduced vaccine effectiveness. Booster vaccination with mRNA vaccines provides over 70% protection against hospitalization and death in breakthrough Omicron infections.

LANCET (2022)

Add to Collection

Article Oncology

Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population- based test-negative case-control study

Lennard Y. W. Lee et al.

Summary: This study evaluated the effectiveness of vaccines against breakthrough SARS-CoV-2 infections in patients with cancer. The results showed that the effectiveness of vaccines in cancer patients is lower compared to the general population.

LANCET ONCOLOGY (2022)

Add to Collection

Review Oncology

Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)

Simone Cesaro et al.

Summary: SARS-CoV-2 infection can lead to severe outcomes in immunocompromised hematological patients, with high mortality rates observed. Treatment strategies focus on controlling viral replication and inflammation. However, the effectiveness and benefits of preventive and therapeutic measures in hematological patients require further investigation.

LEUKEMIA (2022)

Add to Collection

Article Oncology

Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US Between December 2020 and November 2021

William Wang et al.

Summary: This study examined the risk of breakthrough SARS-CoV-2 infections, hospitalizations, and mortality in vaccinated patients with cancer in the US. The results showed significantly increased risks for breakthrough infection in vaccinated cancer patients, especially those undergoing active cancer care, with marked heterogeneity among specific cancer types. Breakthrough infections in cancer patients were associated with significant and substantial risks for hospitalizations and mortality.

JAMA ONCOLOGY (2022)

Add to Collection

Letter Hematology

Immunogenicity and clinical efficacy of anti-SARS-CoV-2 vaccination in patients with hematological malignancies: Results of a prospective cohort study of 365 patients

Marco Salvini et al.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Article Oncology

Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World Evidence From the National COVID Cohort Collaborative

Qianqian Song et al.

Summary: This study provides real-world evidence on the risks and outcomes of breakthrough COVID-19 infections in vaccinated patients with cancer. The study found that patients with cancer, especially those with hematologic malignancies, are at higher risk for developing breakthrough infections and severe outcomes. Vaccination significantly reduces the risk of breakthrough infections in all cancer patients, and Moderna's mRNA-1273 vaccine shows a greater reduction in breakthrough infection risk for patients with multiple myeloma compared to Pfizer's BNT162b2 vaccine.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Adaptive immunity to SARS-CoV-2 and COVID-19

Alessandro Sette et al.

Summary: The adaptive immune system, consisting of B cells, CD4(+) T cells, and CD8(+) T cells, plays varying roles in different viral infections and vaccines. Studies are showing that CD4(+) T cells, CD8(+) T cells, and neutralizing antibodies all play a part in controlling SARS-CoV-2 in COVID-19 cases, emphasizing the importance of understanding adaptive immunity in combating the disease.

CELL (2021)

Add to Collection

Article Oncology

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Livio Pagano et al.

Summary: This study analyzed baseline characteristics and predictors of mortality in hematological malignancy patients with COVID-19. Results showed that a high percentage of patients developed severe/critical symptoms, with a mortality rate of 31.2%, although improved prevention measures have decreased mortality rates despite an increase in reported cases.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.

BLOOD (2021)

Add to Collection

Article Hematology

BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies

Katrin Herzog Tzarfati et al.

Summary: Patients with hematologic malignancies have a reduced immune response to the COVID-19 vaccine, with lower seropositivity rates and antibody titers, increasing their risk for severe infection.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Article Hematology

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies

Paola Ghione et al.

BLOOD (2021)

Add to Collection

Article Hematology

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia

Patrick Harrington et al.

Summary: This study found that most patients with CML developed antibodies and polyfunctional T-cell responses after receiving a single dose of the SARS-CoV-2 BNT162b2 vaccine, demonstrating good immunogenicity in this patient population compared to those with solid tumors or lymphoid hematological malignancies.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Letter Oncology

Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies

Lee Greenberger et al.

CANCER CELL (2021)

Add to Collection

Letter Oncology

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia

Fulvia Pimpinelli et al.

Summary: Among 42 Philadelphia negative myeloproliferative neoplasm patients receiving systemic active treatment, those with myelofibrosis showed significantly lower response to the anti-SARS-CoV-2 BNT162b2 vaccine compared to patients with essential thrombocythemia and polycythemia vera in terms of IgG titers and seroprotection rates. The ongoing treatment with Ruxolitinib in some patients may be associated with reduced vaccine immunogenicity, but further large prospective studies are needed to confirm this finding.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Letter Oncology

Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms

Patrick Harrington et al.

LEUKEMIA (2021)

Add to Collection

Article Medicine, General & Internal

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Moriah Bergwerk et al.

Summary: Among fully vaccinated health care workers, breakthrough infections with SARS-CoV-2 were correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status — Los Angeles County, California, May 1–July 25, 2021

Jennifer B. Griffin et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021

Catherine M. Brown et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma

C. Perry et al.

Summary: Patients with B-cell non-Hodgkin lymphoma (B-NHL) undergoing R/Obi treatment have impaired humoral response to the BNT162b2 mRNA COVID-19 vaccine. Longer time since exposure to R/Obi is associated with improved response rates to the COVID-19 vaccine. Multi-variable analysis reveals predictors for a positive serological response.

BLOOD ADVANCES (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Zunyou Wu et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Hematology

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Francesco Passamonti et al.

LANCET HAEMATOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

E. J. Anderson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Hematology

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

Abi Vijenthira et al.

BLOOD (2020)

Add to Collection

Article Hematology

Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub

William A. Wood et al.

BLOOD ADVANCES (2020)

Add to Collection

© Peeref 2019-2024. All rights reserved.